We describe double-antibody procedures for determining a-fetoprotein in human serum. An equilibrium procedure can be done in 24 h with a sensitivity of at least 4 zg/Iiter and coefficient of variation of 5.5%. There are no interferences from normal human sera or sera with certain commonly seen chemical abnormalities. We also describe and discuss sequential procedures that range in sensitivity from 250 ng to 1 g/Iiter and require 24-48 h incubation. The precise (mid-range) portion of the dose/response curve for sequential procedures can be shifted to higher or lower values by an adjustment of the time of preliminary incubation of antibody with unlabeled antigen. With a 37 #{176}C incubation, a sequential procedure can be completed in 7 h. Sensitivity is 1 .tg/liter, and coefficient of variation 8.0%. The relative merits of the above assay procedures are discussed. The double-antibody radioimmunoassay is twice as sensitive as the Farr procedure [J. Infect. Dis. 103, 239 (1958)], and it is free of the large and variable nonspecific precipitation that accompanies the precipitation of bound antigen with sodium sulfate solution. Double-antibody radioimmunoassay is superior to enzyme immunoassay in both sensitivity and precision. In 1964, Tatarinov (2) detected this fetal protein in the serum of a patient with hepatocellular carcinoma. Using gel techniques similar to Tatarmnov's, other investigators subsequently detected it in serum of patients with embryonal germ cell malignancies (3), hepatitis (4), or cirrhosis (4).
Use of the more sensitive radioimmunoassay procedures later confirmed and extended these earlier findings by demonstrating (a) an increased frequency of association of abnormal values for a-fetoprotein in serum with the above conditions (5, 6) , (b) the presence of a-fetoprotein in serum of normal adults (7, 8) , and (c) the occurrence of a-fetoprotein values significantly exceeding normal in the serum of patients with tumors metastatic to the liver (9, 10).
Determination of a-fetoprotein in amniotic fluid both by various immunodiffusion techniques (11, 12) and by radioimmunoassay (13) established that in cases of fetal neural tube defects such as anencephaly and spina bifida, values were substantially supranormal and such defects could be detected with great accuracy. In this type of birth defect also, radioimmunoassay determined that a-fetoprotein in the mother's serum was also above normal (14) (15) (16) , suggesting that such determinations might be used as a screening test to identify affected pregnancies. By this method, the overall detection rate for neural tube defects is not as high as when the determination is done on amniotic fluid: 80% vs. 90% in anencephaly and 40% vs. 65% for spina bifida (13, 17) . The relative inefficiency of the determination on serum is generally attributed to the difference between values for maternal serum in affected and normal pregnancies being smaller than is the case for amniotic fluid (18, 19) .
A recently published study (20) , however, reports a highly efficient rate of detection, 97% for anencephaly and 92% for spina bifida, when sera from 31 patients with affected fetuses were assayed during the second trimester of pregnancy. This increased efficiency results in part from a careful selection of the time of gestation that the patients's serum is assayed, but may also be a result of the high reproducibility (6%) of the radioimmunoassay procedure, which could facilitate the distinction between normal and abnormal. Further studies of maternal a-fetoprotein are indicated, and it was toward the development of a radioimmunoassay pro-cedure precise and reproducible enough for such studies 
Materials and Methods

Purification of Human a-Fetoprotein and Preparation of Rabbit Antiserum to It
We used a modification 
Assay System and Procedures
The general procedure is that used in other doubleantibody radioimmunoassays.
'I-labeled Ml of dilute second antibody is added to all tubes of the assay system except the protein-bound 1251and antigen clone tubes. Contents of tubes are vortex-mixed and allowed to stand for 6 h at either room temperature or 4 #{176}C, except for the 37 #{176}C sequential procedure, in which the incubation is also at 37 #{176}C and for a period of 1 h. In cases where variation in total counts for the separate samples exceeded the error in the count of the separate fractions, totals for individual samples were used in calculations; otherwise either the mean control count of the mean protein-bound 1251 bound count, each appropriately corrected, was used as the total count. Dose/response curves were plotted as the ratio of the fraction of '251-labeled a-fetoprotein bound at a given dose to the fraction bound at zero dose:
against log dose (micrograms of a-fetoprotein per liter).
Results
Sensitivity of Antibody and Immunoreactivity of 125l-labeled a-Fetoprotein
To determine that the antibody used had the sensitivity to detect the minimum a-fetoprotein concentrations of normal human serum (2 to 4 pg/liter), we ran 
Selection of 1251-labeled a-Fetoprotein Concentration and Sensitivity of Dose/Response Curve
Based on the study of Hunter (27), the minimum sensitivity of radioimmunoassay is generally equal to about twice the dose of labeled antigen, and at this minimum dose, the labeled antigen is bound at 90% of 
Optimization of Specific Activity of the Labeled Antigen
A target specific activity for the 125J labeled a-fetoprotein was selected so that on the average, the precipitate counts and those of 1 ml of the supernate could be counted to an accuracy of 1% in 1 mm or less (10 000 counts). In art assay which binds 50% at maximum, the mean dose binds 25% of the counts, and the total counts in the tube should be about 40 000 to be counted to the desired accuracy in this time. We estimated that labeling could be conveniently performed every six to eight weeks, and that our laboratory demand for 125J labeled a-fetoprotein (allowing for waste and manipulative loss) would be 20 Mg. At the time that the mean assay would be performed, the 1251-labeled cr-fetoprotein would have decayed to 0.75 of its original level.
Ideal specific activity should then be: To detect any interference with the determination of a-fetoprotein in normal human serum, we made up parallel standards from purified a-fetoprotein in both normal goat serum and normal human serum from which cs-fetoprotein had been removed by absorption. We ran dose/response curves, using identical '251-labeled a-fetoprotein and antiserum concentrations and the two sets of standards.
The two curves were coincident (Figure 2 ).
Nonspecific Precipitation and Completeness of Precipitation of Bound 125l-labeled a-Fetoprotein with Second Antibody
The amount of nonspecific precipitation in the absence of both first and second antibody ranged from 1 to 2%; nonspecific precipitation in the absence of first antibody and presence of second antibody ranged from 2 to 3%.
The completeness of precipitation of bound 125I labeled cr-fetoprotein by second antibody was evaluated by removing 1 ml of the supernate from all tubes of a precipitated assay set, adding 0.5 ml of 20 ml/liter normal rabbit serum and 0.5 ml of the dilute second antibody solution.
After 6 h of incubation, bound and free fractions were separated and counted in the usual manner. The amount of I-labeled a-fetoprotein in the bound fraction in no case exceeded that found in the no-antibody control tube in the original assay. 
Specificity and Accuracy
where x = sample recovery, %; = mean recovery, %; n = number of samples.
Precision and Reproducibility
We evaluated within-run variance by determining In an attempt to shorten the incubation time necessary for a sensitive sequential procedure, we allowed standard doses of unlabeled a-fetoprotein and antibody to incubate at 4 #{176}C fQr 16 h, a time at which association studies indicate that more than 85% of the maximum binding of 1.5 ng of '251-labeled a-fetoprotein is reached. Post-incubation with 1251-labeled a-fetoprotein was terminated at 4, 8, 24, and 32 h. A comparative plot of BIT vs. dose for these incubation times (Figure 5A) indicates that there is a sufficient range in the binding of '25I-labeled a-fetoprotein from low to high doses even at 4 h post-incubation to produce a useful dose/response curve ( Figure 5B ). Extending the post-incubation time to equilibrium results in a slight increase in slope and better resolution of values of less than 1 gI1ithr. Midpoint sensitivity was the same for all dose/response curves, no matter how long the period of post-incubation.
To demonstrate that the linear position of the dose/response curve in which dose estimates are made most precisely5 can be shifted in range, the sequential procedure was altered by shortening the time of the preincubation to 6 h at room temperature, a point at which a 1.5-ng dose was shown to be bound to 70% of maximum. At this time 1251-labeled a-feteprotein was added and allowed to incubate overnight, after which the assay was terminated.
This manipulation shifted the linear portion of the dose/response curve to a range inKirkpatrick, K., and Kirkpatrick, A., Selection of optimal doseresponse curve for radioimmunoassay data. (In preparation). The pre-and post-incubation times were selected because they conform to normal 8-h working day schedules, but experience with the assay described previously indicates that the dose/response curve would still be usable if the post-incubation period were shorter.
The time required to perform the assay can be considerably shortened by incubating at 37 #{176}C. The conditions of the rapid 37 #{176}C sequential assay are similar to the 40-h sequential procedure in that the preliminary incubation is for a period of time (4 h) during which the a-fetoprotein dose as determined by previous studies with labeled antigen binds to 85% of maximum. However, since dissociation of the antigenantibody complex is significant under the conditions of the assay, binding of 1251-labeled a-fetoprotein presumably occurs through this mechanism as well as through the binding of excess available antibody.
A comparison of the dose/response curves for the equilibrium procedure and the various sequential procedures is shown in Figure 6 and Table 1 . 
Comparison to Other Assays
As an assessment of the suitability of this doubleantibody radioimmunoassay for the determination of a-fetoprotein in human sera, it was compared to two other assay procedures.
Comparison with another radioimmunoassay procedure.
The double-antibody radioimmunoassay was compared to a similar assay developed by Wepsic.6 The latter procedure was one terminated by a salting-out of the antigen-antibody complex with Na2SO4 (160 g/liter) solution, rather than by immunoprecipitation. Dose/ response curves for the two assays were run under identical conditions, using the same standards and dose of '251-labeled a-fetoprotein. The first antibody used in the salting-out procedure was raised in a goat by using purified a-fetoprotein prepared by another laboratory. The two dose/response curves were similar in shape and slope, the only difference being one of sensitivity ( Figure   7 ). 
Clinical Assessment: a-Fetoprotein in Pregnancy
Serial measurements of a-fetoprotein in serum were made during two pregnancies by taking serum samples at least biweekly, in one case from the 8th week of pregnancy until two weeks after delivery, and in the other from the 10th through the 27th week (Figure 10 ). In the first case, a-fetoprotein concentrations in serum increased above the normal at about 13 weeks of pregnancy, and advanced to 60 gfliter by the end of the first trimester. Preliminary efforts to adapt these double-antibody radioimmunoassay procedures to automation by using a Micro-Medic apparatus have been highly successful.
